Compare FLXS & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLXS | CRBU |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.8M | 203.9M |
| IPO Year | N/A | 2021 |
| Metric | FLXS | CRBU |
|---|---|---|
| Price | $40.48 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 27.7K | ★ 961.5K |
| Earning Date | 02-02-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | ★ 64.53 | N/A |
| EPS | ★ 4.11 | N/A |
| Revenue | ★ $447,505,000.00 | $9,295,000.00 |
| Revenue This Year | $4.11 | N/A |
| Revenue Next Year | $3.04 | $3.62 |
| P/E Ratio | $9.98 | ★ N/A |
| Revenue Growth | ★ 6.00 | N/A |
| 52 Week Low | $29.38 | $0.66 |
| 52 Week High | $64.14 | $3.54 |
| Indicator | FLXS | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 54.61 | 45.15 |
| Support Level | $38.57 | $1.63 |
| Resistance Level | $41.43 | $1.80 |
| Average True Range (ATR) | 1.38 | 0.08 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 71.88 | 53.85 |
Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.